Literature DB >> 7511172

Duck hepatitis B virus infection of Muscovy duck hepatocytes and nature of virus resistance in vivo.

J C Pugh1, H Simmons.   

Abstract

To test the hypothesis that in vivo resistance to hepadnavirus infection was due to resistance of host hepatocytes, we isolated hepatocytes from Muscovy ducklings and chickens, birds that have been shown to be resistant to duck hepatitis B virus (DHBV) infection, and attempted to infect them in vitro with virus from congenitally infected Pekin ducks. Chicken hepatocytes were resistant to infection, but we were able to infect approximately 1% of Muscovy duck hepatocytes in culture. Infection requires prolonged incubation with virus at 37 degrees C. Virus spread occurs in the Muscovy cultures, resulting in 5 to 10% DHBV-infected hepatocytes by 3 weeks after infection. The relatively low rate of accumulation of DHBV DNA in infected Muscovy hepatocyte cultures is most likely due to inefficient spread of virus infection; in the absence of virus spread, the rates of DHBV replication in Pekin and Muscovy hepatocyte cultures are similar. 5-Azacytidine treatment can induce susceptibility to DHBV infection in resistant primary Pekin hepatocytes but appears to have no similar effect in Muscovy cultures. The relatively inefficient infection of Muscovy duck hepatocytes that we have described may account for the absence of a detectable viremia in Muscovy ducklings experimentally infected with DHBV.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7511172      PMCID: PMC236726     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  14 in total

1.  Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification.

Authors:  J Summers; P M Smith; A L Horwich
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

2.  Infection and uptake of duck hepatitis B virus by duck hepatocytes maintained in the presence of dimethyl sulfoxide.

Authors:  J C Pugh; J W Summers
Journal:  Virology       Date:  1989-10       Impact factor: 3.616

3.  Suramin inhibits in vitro infection by duck hepatitis B virus, Rous sarcoma virus, and hepatitis delta virus.

Authors:  D J Petcu; C E Aldrich; L Coates; J M Taylor; W S Mason
Journal:  Virology       Date:  1988-12       Impact factor: 3.616

Review 4.  DNA methylation and gene function.

Authors:  A Razin; A D Riggs
Journal:  Science       Date:  1980-11-07       Impact factor: 47.728

5.  In vitro recombinants of ground squirrel and woodchuck hepatitis viral DNAs produce infectious virus in squirrels.

Authors:  C Seeger; P L Marion; D Ganem; H E Varmus
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

6.  In vitro infection of human hepatoma (HepG2) cells with hepatitis B virus.

Authors:  R Bchini; F Capel; C Dauguet; S Dubanchet; M A Petit
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

7.  Duck hepatitis B virus (DHBV) particles produced by transient expression of DHBV DNA in a human hepatoma cell line are infectious in vitro.

Authors:  J C Pugh; K Yaginuma; K Koike; J Summers
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

8.  Efficient duck hepatitis B virus production by an avian liver tumor cell line.

Authors:  L D Condreay; C E Aldrich; L Coates; W S Mason; T T Wu
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

9.  Cellular differentiation, cytidine analogs and DNA methylation.

Authors:  P A Jones; S M Taylor
Journal:  Cell       Date:  1980-05       Impact factor: 41.582

10.  Transmission of ground squirrel hepatitis virus to homologous and heterologous hosts.

Authors:  D Trueba; M Phelan; J Nelson; F Beck; B S Pecha; R J Brown; H E Varmus; D Ganem
Journal:  Hepatology       Date:  1985 May-Jun       Impact factor: 17.425

View more
  9 in total

1.  Duck hepatitis B virus virion secretion requires a double-stranded DNA genome.

Authors:  David Perlman; Jianming Hu
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

Review 2.  Avian hepatitis B viruses: molecular and cellular biology, phylogenesis, and host tropism.

Authors:  Anneke Funk; Mouna Mhamdi; Hans Will; Hüseyin Sirma
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

3.  The pre-S domain of the large viral envelope protein determines host range in avian hepatitis B viruses.

Authors:  T Ishikawa; D Ganem
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

4.  Residues critical for duck hepatitis B virus neutralization are involved in host cell interaction.

Authors:  C Sunyach; C Rollier; M Robaczewska; C Borel; L Barraud; A Kay; C Trépo; H Will; L Cova
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

5.  Interaction between duck hepatitis B virus and a 170-kilodalton cellular protein is mediated through a neutralizing epitope of the pre-S region and occurs during viral infection.

Authors:  S Tong; J Li; J R Wands
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  Detection of duck hepatitis B virus DNA on filter paper by PCR and SYBR green dye-based quantitative PCR.

Authors:  Chi-Young J Wang; Joseph J Giambrone; Bruce F Smith
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

7.  Susceptibility to duck hepatitis B virus infection is associated with the presence of cell surface receptor sites that efficiently bind viral particles.

Authors:  J C Pugh; Q Di; W S Mason; H Simmons
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

8.  Glycine decarboxylase mediates a postbinding step in duck hepatitis B virus infection.

Authors:  Jisu Li; Shuping Tong; Hong Bock Lee; Ana Luisa Perdigoto; Hans Christian Spangenberg; Jack R Wands
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

9.  New hepatitis B virus of cranes that has an unexpected broad host range.

Authors:  Alexej Prassolov; Heinz Hohenberg; Tatyana Kalinina; Carola Schneider; Lucyna Cova; Oliver Krone; Kai Frölich; Hans Will; Hüseyin Sirma
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.